Sir Christopher Evans, a leading name in biotech, is close to landing $50 million in fresh funding for Ellipses Pharma. This investment puts the London-based cancer drug company on track for a major IPO in Hong Kong.
The company’s valuation now approaches $800 million, making this its final fundraising round before going public.
Why Investors Are Flocking to Ellipses Pharma
Ellipses Pharma focuses on developing cutting-edge cancer treatments. Its portfolio has attracted global attention from both Middle Eastern and Asian investors.
Earlier, Sir Tom Hunter’s West Coast Capital invested in the firm, boosting its profile further.
Additionally, the company’s board includes a member from Mubadala, Abu Dhabi’s powerful sovereign wealth fund. This reinforces its reputation as a high-stakes biotech venture.
UAE Trial Launch and Global Expansion
In December, Ellipses launched clinical trials in the UAE. This milestone marked a key step toward international reach.
“We can now bring hope and innovative therapy to people in the UAE,” said Sir Christopher Evans.
Furthermore, the trial supports collaboration between doctors and researchers, opening new doors for global research.
Why the Hong Kong IPO Makes Strategic Sense
The upcoming IPO will likely be hosted in Hong Kong. The city is quickly becoming a preferred biotech listing hub, especially for companies with international investors.
This move not only offers capital but also strengthens Ellipses’ access to Asian markets.
What’s Next for Ellipses Pharma?
This $50M round is expected to be the last private funding before the IPO. The money will help drive ongoing trials and accelerate research.
As the company moves forward, it will focus on bringing life-saving therapies to market quickly, while deepening investor confidence.
